PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
9.43%
Revenue growth above 1.5x AVGO's 1.23%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
9.99%
Positive gross profit growth while AVGO is negative. John Neff would see a clear operational edge over the competitor.
29.39%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
29.39%
Positive operating income growth while AVGO is negative. John Neff might view this as a competitive edge in operations.
29.08%
Net income growth under 50% of AVGO's 84.10%. Michael Burry would suspect the firm is falling well behind a key competitor.
33.33%
EPS growth under 50% of AVGO's 83.33%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
20.48%
Diluted EPS growth under 50% of AVGO's 92.98%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-0.56%
Share reduction while AVGO is at 1.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
5.70%
Diluted share count expanding well above AVGO's 0.68%. Michael Burry would fear significant dilution to existing owners' stakes.
0.56%
Dividend growth 1.25-1.5x AVGO's 0.39%. Bruce Berkowitz would see if management’s capital return strategy is more aggressive yet sustainable.
-40.45%
Negative OCF growth while AVGO is at 17.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-40.16%
Negative FCF growth while AVGO is at 29.09%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
104.35%
10Y revenue/share CAGR under 50% of AVGO's 584.60%. Michael Burry would suspect a lasting competitive disadvantage.
58.19%
5Y revenue/share CAGR under 50% of AVGO's 339.67%. Michael Burry would suspect a significant competitive gap or product weakness.
60.18%
3Y revenue/share CAGR under 50% of AVGO's 272.28%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
964.73%
10Y OCF/share CAGR at 75-90% of AVGO's 1173.64%. Bill Ackman would demand strategic changes to close the gap in long-term cash generation.
152.62%
Below 50% of AVGO's 354.24%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
109.07%
3Y OCF/share CAGR under 50% of AVGO's 292.80%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
186.92%
Below 50% of AVGO's 853.70%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
87.97%
5Y net income/share CAGR at 75-90% of AVGO's 98.81%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
187.54%
3Y net income/share CAGR above 1.5x AVGO's 73.45%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
166.39%
Below 50% of AVGO's 1260.82%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
36.74%
Below 50% of AVGO's 442.73%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
17.70%
Below 50% of AVGO's 283.59%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
56.80%
Below 50% of AVGO's 300.26%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
23.14%
AR growth well above AVGO's 6.47%. Michael Burry fears inflated revenue or higher default risk in the near future.
32.23%
We show growth while AVGO is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
4.97%
Asset growth above 1.5x AVGO's 0.47%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
7.37%
BV/share growth above 1.5x AVGO's 0.51%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-0.07%
We’re deleveraging while AVGO stands at 0.04%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
1.16%
R&D dropping or stable vs. AVGO's 2.60%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-1.26%
We cut SG&A while AVGO invests at 1.49%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.